Non-invasive Urine Test for Molecular Classification of Clinical Significance in Newly Diagnosed Prostate Cancer Patients

• Published in: Frontiers in medicine Vol. 8; p. 721554
• Main Authors: Guo, Jinan, Zhang, Xuhui, Xia, Taolin, Johnson, Heather, Feng, Xiaoyan, Simoulis, Athanasios, Wu, Alan H. B., Li, Fei, Tan, Wanlong, Johnson, Allan, Dizeyi, Nishtman, Abrahamsson, Per-Anders, Kenner, Lukas, Xiao, Kefeng, Zhang, Heqiu, Chen, Lingwu, Zou, Chang, Persson, Jenny L.
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 14-09-2021
• Subjects: active surveillance; Clinical Medicine; clinically significant prostate cancer; gene panel; Klinisk medicin; liquid biopsy; Medical and Health Sciences; medicin; Medicin och hälsovetenskap; Medicine; prostate cancer; prostate cancer risk; urine test; Urologi och njurmedicin; Urology and Nephrology
• ISSN: 2296-858X; 2296-858X
• DOI: 10.3389/fmed.2021.721554

Objective:
To avoid over-treatment of low-risk prostate cancer patients, it is important to identify clinically significant and insignificant cancer for treatment decision-making. However, no accurate test is currently available.
Methods:
To address this unmet medical need, we developed a novel gene classifier to distinguish clinically significant and insignificant cancer, which were classified based on the National Comprehensive Cancer Network risk stratification guidelines. A non-invasive urine test was developed using quantitative mRNA expression data of 24 genes in the classifier with an algorithm to stratify the clinical significance of the cancer. Two independent, multicenter, retrospective and prospective studies were conducted to assess the diagnostic performance of the 24-Gene Classifier and the current clinicopathological measures by univariate and multivariate logistic regression and discriminant analysis. In addition, assessments were performed in various Gleason grades/ISUP Grade Groups.
Results:
The results showed high diagnostic accuracy of the 24-Gene Classifier with an AUC of 0.917 (95% CI 0.892–0.942) in the retrospective cohort (
n
= 520), AUC of 0.959 (95% CI 0.935–0.983) in the prospective cohort (
n
= 207), and AUC of 0.930 (95% 0.912-CI 0.947) in the combination cohort (
n
= 727). Univariate and multivariate analysis showed that the 24-Gene Classifier was more accurate than cancer stage, Gleason score, and PSA, especially in the low/intermediate-grade/ISUP Grade Group 1–3 cancer subgroups.
Conclusions:
The 24-Gene Classifier urine test is an accurate and non-invasive liquid biopsy method for identifying clinically significant prostate cancer in newly diagnosed cancer patients. It has the potential to improve prostate cancer treatment decisions and active surveillance.